Clinical Trial Update: Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE [Phase 3]

View source ↗

Summary

Phase 3 trial update for BCX7353 as an oral preventive treatment for hereditary angioedema (HAE) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• BCX7353

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Hereditary Angioedema, HAE | Phase 3 | Status: COMPLETED | Results posted: 2021-03-02